Wells Fargo & Company Vaxxinity, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.62 - $0.86 $1,056 - $1,465	1,704 Added 15.45%	12,731 $9,000
Q4 2023 Feb 09, 2024	BUY	$0.7 - $1.31 $1,759 - $3,292	2,513 Added 29.52%	11,027 $9,000
Q3 2023 Nov 13, 2023	SELL	$1.25 - $3.0 $11,528 - $27,669	-9,223 Reduced 52.0%	8,514 $11,000
Q2 2023 Aug 15, 2023	BUY	$1.73 - $2.79 $30,255 - $48,794	17,489 Added 7052.02%	17,737 $44,000
Q1 2023 May 12, 2023	BUY	$1.43 - $4.24 $5 - $16	4 Added 1.64%	248 $0
Q4 2022 Feb 13, 2023	BUY	$1.31 - $2.62 $7 - $15	6 Added 2.52%	244 $0
Q3 2022 Nov 14, 2022	BUY	$1.64 - $2.48 $390 - $590	238 New	238 $0

469K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $2.24M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.